Welcome to our dedicated page for Clearmind Medicine SEC filings (Ticker: CMND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Clearmind Medicine's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Clearmind Medicine's regulatory disclosures and financial reporting.
Clearmind Medicine Inc. reported progress in its ongoing FDA-approved Phase I/IIa clinical trial of CMND-100, a proprietary non-hallucinogenic MEAI-based oral drug candidate for Alcohol Use Disorder. The company has successfully completed treatment and follow-up for 18 participants, marking a key early-stage milestone in assessing safety, tolerability, pharmacokinetics, and preliminary efficacy.
Clearmind also completed treatment for four additional participants at its Tel Aviv clinical center, highlighting expanding enrollment and operational strength at its Israeli sites. The trial is being run at leading institutions including Yale University, Johns Hopkins University, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. Clearmind describes itself as a clinical-stage neuroplastogens pharmaceutical biotech with nineteen patent families and 31 granted patents focused on non-hallucinogenic, second-generation therapeutics for underserved conditions such as Alcohol Use Disorder.
Clearmind Medicine Inc., a clinical-stage biotech company focused on non-hallucinogenic, second-generation neuroplastogen-derived therapeutics, has filed a patent application in India for innovative psychedelic-based compounds aimed at treating mental health disorders and addiction. The application, submitted to the Indian Patent Office, extends the company’s global intellectual property portfolio and builds on its exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.
The patent seeks to protect novel compounds designed to address limitations of classical psychedelics, with the goal of providing potentially safer, more effective and scalable treatments for underserved mental health and addictive conditions. Clearmind reports that its intellectual property portfolio currently includes nineteen patent families and 31 granted patents, and it plans to continue pursuing additional patents and related IP opportunities.
Clearmind Medicine Inc. files a post-effective amendment registering the resale of up to 331,949 common shares issuable upon exercise of January 2024 PIPE Warrants. The prospectus combines previously effective registration statements and covers shares issuable from time to time upon warrant exercise.
The selling shareholders will receive net proceeds from any resale; the company will not receive proceeds unless warrants are exercised for cash. The filing notes 2,394,806 common shares outstanding as of March 24, 2026 and states the registered shares equal approximately 15.89% of outstanding shares prior to the offering.
Clearmind Medicine Inc. files a post-effective amendment registering up to 331,949 common shares for resale by selling shareholders, representing shares issuable upon exercise of January 2024 PIPE Warrants, upon effectiveness.
The combined prospectus consolidates prior registrations and updates warrant adjustments following financings and a one-for-40 reverse split. The company will not receive proceeds from resales; however, it may receive proceeds if warrants are exercised for cash. The filing discloses 2,394,806 common shares outstanding as of March 24, 2026 and lists selling holders with per-holder maximums and 4.99%/9.99% beneficial ownership limits on warrant exercises.
Clearmind Medicine Inc. reported continued progress in the third cohort of its FDA-approved Phase I/IIa trial of CMND-100, a non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder. Patients at Yale University and Johns Hopkins University are moving through treatment with no serious adverse events reported to date, supporting the drug’s early safety and tolerability profile.
The multinational, multicenter study is designed to assess safety, tolerability, pharmacokinetics, and preliminary efficacy in moderate to severe Alcohol Use Disorder. Clearmind describes itself as a clinical-stage neuroplastogens-focused biotech with an intellectual property portfolio of nineteen patent families, including 31 granted patents.
Clearmind Medicine Inc. reported that the Intellectual Property Department in Hong Kong has published six patents covering its next-generation psychedelic-based combination therapies. These patents center on formulations that pair Palmitoylethanolamide (PEA), supplied through its partnership with NeuroThera Labs, with several classic and innovative psychedelic compounds.
The combinations include PEA with MDMA, LSD, ketamine, ibogaine, psilocybin and DMT, aiming to enhance therapeutic potential and neuroplasticity while potentially improving safety and tolerability. Clearmind describes itself as a clinical-stage neuroplastogens biotech with an intellectual property portfolio of nineteen patent families, including 31 granted patents.
L.I.A. Pure Capital Ltd. filed an amendment to a Schedule 13G reporting beneficial ownership in Clearmind Medicine Inc. The filing states 108,720 Common Shares, representing 5.0% of the class based on 2,088,806 shares outstanding as of the reporting date. The position consists of 20,470 currently held Common Shares, 93,231 shares issuable upon conversion of a convertible promissory note at a $1.25 floor conversion price, and 229,000 shares exercisable under a pre-funded warrant; exercise/conversion are subject to a 4.99% beneficial ownership blocker. The amendment is signed by Kfir Silberman as CEO on 03/16/2026.
Clearmind Medicine Inc. schedule filing: Capitalink Ltd. reports beneficial ownership of 107,943 Common Shares, representing 5.0% based on 2,088,806 shares outstanding as stated in the filing.
The filing breaks the position into (i) 32,693 Common Shares held, (ii) 93,231 Common Shares issuable upon conversion of a convertible promissory note at a $1.25 conversion price, and (iii) 229,000 Common Shares that may be acquired upon exercise of a pre-funded warrant, each within 60 days. The note and warrant include a blocker provision limiting ownership to "more than 4.99%" when combined with affiliates.
Clearmind Medicine Inc., a clinical-stage biotech company, filed a patent application in Hong Kong for a new combination therapy targeting major depressive disorder. The therapy pairs its proprietary compound 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA), sourced through its partnership with NeuroThera Labs Inc.
The company highlights this MEAI-PEA approach as a non-hallucinogenic neuroplastogen-based option intended to address depression, which affects more than 332 million people worldwide, within a market expected to surpass $25 billion by 2030. Clearmind notes it currently holds nineteen patent families, including 31 granted patents, and plans to continue expanding its intellectual property portfolio.
Clearmind Medicine Inc. reported unaudited results for the three months ended January 31, 2026, showing a net loss of $3.85 million with no revenue, compared with a $1.07 million loss a year earlier. Operating expenses rose to $3.66 million, mainly from higher general and administrative and research and development costs.
Cash and cash equivalents increased to $9.26 million and working capital to $8.12 million, driven by equity issuances, warrant exercises and conversion of convertible loans into shares, which reduced total liabilities to $2.91 million. The company is funding phase I/IIa trials of its CMND‑100 psychedelic treatment for Alcohol Use Disorder, where an independent safety board approved continuation after a positive interim safety review.
Management notes negative operating cash flows of $2.08 million, an accumulated deficit of $31.73 million, and dependence on additional financing, stating that these conditions raise substantial doubt about Clearmind’s ability to continue as a going concern, even though the financial statements are prepared on a going-concern basis.